Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer

Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy.

Related Keywords

Florida ,United States ,Miami Beach ,Nuvation Bio ,Genentech Incyte ,Selinexor Xpovio ,Brian Slomovitz ,Gynecologic Oncology At Mount Sinai Medical Center ,Glaxosmithkline ,Astrazeneca ,Plenary Series ,Gynecologic Oncology ,Mount Sinai Medical Center ,Myriad Genetics ,Onconova Therapeutics ,Selinexor ,Patients With Tp53 Wild Type Advanced Or Recurrent Endometrial Cancer ,Siendo Trial ,Nct03555422 ,D ,